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FLT-PETObjective: The role of F-18-ﬂuorothymidine (FLT) PET-CT imaging in the evaluation of gynecologic cancers has
not been established.We sought to evaluate (FLT) PET-CT imaging in gynecologic cancers by comparing standard
uptake values (SUVs) of FLT with F-18-ﬂuorodeoxyglucose (FDG) PET in the primary tumor at diagnosis, and as-
sess FLT uptake immediately following concurrent chemoradiotherapy (chemoRT).
Methods: In this pilot study, patients treated for cervical (5) or vaginal (1) cancer underwent FLT-PET and FDG-
PET scanning at diagnosis (FLT1 and FDG1). Five patients (4 cervical and 1 vaginal) also underwent FLT-PET
within 1–3 weeks after chemoRT before brachytherapy (FLT2). Wilcoxon rank-sum test was used to compare
the FLT1 and FDG1 parameters.
Results:Median age at diagnosis was 61-years (range, 33–72). Cervical cancers were staged as IB2 (n= 1, 20%),
IIB (n = 1, 20%), IIIB (n = 1, 20%) and IVA (n = 2, 40%) and the single vaginal cancer was staged IIIB. The most
common histology was squamous cell carcinoma (n = 3, 50%) followed by adenocarcinoma (n = 2, 33%) and
clear-cell adenosquamous carcinoma (n = 1, 17%). Median tumor SUVmax at diagnosis was 7.8 on FLT1-PET
(3.9–14.2) versus 11.6 (5.9–23.2) on FDG1-PET (p = 0.15). Tumor SUVmax of FLT declined 54%–100% after
chemoRT.
Conclusion: The tumor SUV of FLT at diagnosis was lower than that of FDG-PET. FLT uptake was markedly de-
creased after chemoRT. Results indicate that there may not be a signiﬁcant effect of inﬂammation on FLT uptake
in gynecologic cancers. FLTmay be a useful tool when assessing the effects of chemoRT on gynecologicmalignan-
cies and planning for postchemoRT brachytherapy treatments.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gynecologic malignancies, including cervical and vaginal cancers,
often require amultidisciplinary approach that combines radiation, che-
motherapy and/or surgery. Imaging modalities that can accurately
assess the extent of the disease and the effect of treatments have be-
come an integral component in evaluating the success of therapy.
Radiation therapy is an essential component in the management
of unresectable locally advanced disease. More speciﬁcally, external
beam radiation therapy (EBRT) and brachytherapy (BT) are the two
radiation modalities that are used sequentially to reduce the risk ofHealth R21 167800 to A. V.
nd provided support for the
ncology, Brigham and Women's
ited States.
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. This is an open access article underlocal recurrence and improve survival. At diagnosis, positron emission
tomography/computed tomography (PET/CT) with the tracer 2-
[ﬂuorine-18]ﬂuoro-2-deoxy-D-glucose (FDG) is typically used to detect
disease extent. However, studies have indicated that, when FDG-PET is
used immediately after EBRT to assess treatment response, it may be
difﬁcult to differentiate between residual or recurrent active tumor
and inﬂammation in the area treated with radiation using this tracer
(Choi et al., 2014). Therefore, FDG-PET is not a reliable assessment
tool to monitor residual tumor and to direct BT doses immediately
after EBRT.
Another available PET tracer used for tumor assessment, F-18-
ﬂuorothymidine (FLT), has the potential to improve detection of meta-
bolically active tumors (Wang et al., 2015; Hoshikawa et al., 2015). This
relatively new radiotracer has attracted attention for evaluation of post-
radiation response in, head/neck, esophageal, breast, lung, and rectal
cancers though its role in the evaluation of gynecologic cancers after
EBRT is unknown (Yue et al., 2010; Lubberink et al., 2012; Wieder
et al., 2007; Kahraman et al., 2011; Menda et al., 2009). The fact thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient summary.
Patient Age
(yrs)
Stage Primary Histology Chemotherapy
regimen/cycles
EBRT dose
(Gy)
A 72.0 IIIB Vagina SCC CDDP/5 4500
B 33.0 IB2 Cervix CC CDDP/5 4500
C 72.0 IIB Cervix SCC CDDP/5 4500
D 49.0 IIIB Cervix ACC CDDP/5 4500
E 59.0 IVA Cervix ACC CDDP/4 4500
F 64.0 IVA Cervix SCC CPT/3 4500
EBRT = external beam radiotherapy, Gy = gray, SCC = squamous cell carcinoma, CC =
clear-cell carcinoma, ACC = adenocarcinoma; CDDP= cisplatin, CPT = carboplatin.
Table 2
Tumor size and scan time point.
Tumor size Median
MR (n = 5, 83%) 4.06
CT (n = 1, 17%) 6.00
Time between FDG1 and chemoRT start (days) 19 (11–22)
Time between FLT1 and chemoRT start (days) 4 (1–16)
Time between chemoRT end and FLT2 (days) 8 (1–21)
Time between FDG1 and FLT1 (days) 12 (4–19)
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poration in DNA synthesis makes FLT imaging a particularly attractive
tool when differentiating between residual/recurrent malignancy and
inﬂammation (Rasey et al., 2002; Toyohara et al., 2002). The goals of
this study were to compare metabolic parameter standard uptake
values (SUVs) of FLT with FDG PET in patients with gynecologic cancer
at diagnosis and to determine if FLT SUVs are affected by inﬂammation
immediately following EBRT.
2. Material and methods
2.1. Patients
Between August 2012 and April 2014, six patients with newly diag-
nosed gynecologic cancers treated with concurrent chemoradiotherapy
(chemoRT) were enrolled on a prospective clinical trial for image-
guided brachytherapy. All tumors were staged according to the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) 2009 staging
system (Pecorelli, 2009).The eligibility requirements included: histo-
pathologically conﬁrmed primary lesions (ﬁve were cervical cancers
and one was vaginal cancer); MRI and/or PET-CT scan within 4 months
before registration; age ≥18; ECOG performance status ≤2; and no un-
controlled illness thatwould limit compliancewith study requirements.
The study was approved by the institutional review board, and all par-
ticipants signed an informed consent form. The clinicaltrials.gov identi-
ﬁcation number for this trial is NCT01399658.
2.2. FLT synthesis
The BWH Cyclotron and Radiopharmacy produced FLT in a nucleo-
philic synthesis box using in-process controls such as high-purity sol-
vents to synthesize the radiopharmaceutical and automated software
that controls the temperature and timing parameters and records the
information from the production run. An integrity test was performed
on the sterilizing ﬁlter in addition to a sterility test on the ﬁnal drug
product; the process achieved a radiochemical purity of more than 95%.
2.3. PET/CT acquisition
For both FDG and FLT imaging, PET/CT was performed after at least
4 h of fasting and 60 ± 10 min after the intravenous administration of
370–480 megabecquerels of FDG or 296–370 megabecquerels of FLT.
PET imaging was performed in 3-dimensional mode on a Discovery
ST PET/CT scanner (General Electric, Milwaukee, WI) from the skull
base through the mid thighs. Non-contrast helical CT imaging was
performed over the same range without breath-hold for attenuation
correction of PET images and anatomic correlation. The review of FDG-
and FLT-PET/CT images and measurements of the tumor SUVmax were
performed on Hermes workstation (Hermes Medical Solutions AB,
Stockholm, Sweden).
2.4. Statistical analysis
The Wilcoxon rank sum test was used to compare the SUVs of FLT
and FDG at diagnosis. P values of less than 0.05 were considered
signiﬁcant.
3. Results
3.1. Patient and tumor characteristics
Themedian age at diagnosis for the six patients was 61 years (range,
33–72). The ﬁve cervical cancers were staged as IB2 (n = 1, 20%),
IIB (n = 1, 20%), IIIB (n = 1, 20%) and IVA (n = 2, 40%) and the one
vaginal cancer was stage IIIB (n = 1). The most common histology
was squamous cell carcinoma (n=3, 50%) followed by adenocarcinoma(n = 2, 33%) and clear cell adenosquamous carcinoma (n = 1, 17%).
Median follow-up time was 24 months (range, 6–30 months).
All six patients received concurrent weekly chemotherapy (cisplatin
for 5 and carboplatin for 1)with radiation therapy (Table 1). All received
a total radiation dose of 45 Gy in 25 fractions of 1.8 Gy to the pelvis and
para-aortic nodes. Patient A received an additional 6 Gy boost to the
right inguinal nodes, and patient B received an additional 10 Gy boost
to the right iliac nodes.
All patients underwent FLT-PET and FDG-PET scanning at diagnosis;
these scans were performed 1–3 weeks before chemoRT. All patients
also had post-chemoRT FLT-PET/CT scans before receiving brachythera-
py, except patient C due to scanner malfunction (Table 2). All patients
had post-chemoRT FDG-PET, but are not reported due to diffuse uptake.
At last follow-up, ﬁve patients were alive and one had died with the
most recent MRI exam showing signiﬁcant tumor shrinkage 3-months
prior to death but the causewas undeterminable. Two patients with pri-
mary cervical cancer were known to have had recurrence: 1 in the vag-
inal cuff (Patient C) and 1withmetastatic disease to the lung (PatientD).3.2. Comparison of FLT and FDG uptake at diagnosis
At diagnosis, FDG uptake was visually more vivid in the primary
tumor in all patients than FLT uptake (Fig. 1). The median SUVmax at di-
agnosiswas 6.9 (range, 3.9–14.2) for FLT-PET and 11.6 (range, 5.9–23.2)
for FDG-PET. SUVs were 1.5–3.5 times higher for FDG than for FLT in
4 patients; the other two patients only had minor differences between
the SUVs of the two tracers. The difference between the medians was
not statistically signiﬁcant (p = 0.15 by Wilcoxon rank sum test),
which may be due to the small sample size.3.3. Changes in FLT uptake after chemoRT
Overall, FLT accumulation in primary showed signiﬁcant decrease
after chemoRT both visually and quantitatively. In 4 of the 5 patients
who underwent FLT PET after chemoRT, SUVmax of FLT declinedmoder-
ately to markedly. These declines measured 54% (patient A, from
SUVmax of 6.9 to 3.2), 70% (patient D, from 3.9 to 1.2), 81% (patient B,
from 8.7 to 1.7), and 85% (patient E, from 6.0 to 0.9) (Fig. 2). The re-
maining patient F was assessed to have complete resolution of all tu-
mors on both CT and FLT PET, and therefore SUVmax was not measured.
Fig. 1. FLT- and FDG-PET images at diagnosis and post-chemoRT of patientswith: stage IIIB vaginal cancer (A) and stages IB2 (B), IIB (C) IIIB (D) and IVA (E and F) cervical cancer. (Patient C
did not have post-chemoRT FLT scans.) Blue outlines tumor and yellow traces around the bladder. Values at the lower right corner indicate SUVmax.
Fig. 2. Changes in SUVmax uptake of FLT-PET at diagnosis and postchemoRT. Patient F had
complete response. Patient C did not have postchemoRT scans.
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In this small pilot evaluation of the role of FLT-PET in imaging gyne-
cologic tumors, we found that FLT uptake in gynecologic cancers before
treatment was slightly lower than that of FDG but high enough to be
detected and assessed visually and quantitatively. Furthermore, there
was a considerable decrease in FLT uptake after chemoRT in all patients
who had post-chemoRT scans, suggesting no signiﬁcant inﬂuence of
radiation-induced inﬂammation on FLT uptake.
Greatly increased cell proliferation is a characteristic of many ma-
lignant lesions and this cancer-speciﬁc process has been exploited in
tracer imaging. Retention of FLT, an analog of thymidine, has been
shown to correlate with thymidine uptake and thymidine kinase-1
(TK1) activity in cancer cells (Rasey et al., 2002; Toyohara et al.,
2002). The fact that only proliferating cells enable thymidine incorpora-
tion in DNA synthesis (as opposed to glucose utilization, which is in-
creased in both malignant tissue and inﬂammatory tissue) makes FLT
imaging a particularly attractive tool when differentiating between
residual/recurrent malignancy and inﬂammation.
FLT has previously been shown to be not as signiﬁcantly affected by
post-radiation inﬂammation and a more speciﬁc tracer than FDG when
assessing response to radiation therapy, whereas FDG uptake is higher
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example, in laryngeal cancers, FDG uptake was higher than FLT uptake
at diagnosis both visually and quantitatively (Been et al., 2009). On
the other hand, Kishino et al. found on their mid-treatment scans per-
formed after 40 Gy of radiation therapy that abnormal FLT uptake disap-
peared in 63% of head-and-neck squamous cell carcinoma lesions
whereas FDG uptake disappeared in only 16% of the lesions; speciﬁcity
was 72% for FLT compared to 19% for FDG. The speciﬁcity of FLT-PET
(80%) performed after completion of chemoradiation was also higher
than that of FDG-PET (48%). However, the sensitivities of mid-treatment
and post-RT FLT-PET scans (87.5% and 89%, respectively) were both
lower than those of the equivalent FDG-PET scans (100% for both)
(Kishino et al., 2012). VanWaarde et al. found similar results in an animal
study; using an acute-inﬂammation model in rats, they demonstrated
that FLT is amore cancer-speciﬁc PET tracer than FDG, showingnouptake
in inﬂammatory tissues (van Waarde et al., 2004). However, the useful-
ness of FLT imaging in gynecologic cancers has not been evaluated to
date in the setting of post-radiation inﬂammation. Our results show sim-
ilar trendswhen compared to those in othermalignancies reported in the
literature, such as those for laryngeal and head-and-neck cancer cited
above (Been et al., 2009; Kishino et al., 2012; van Waarde et al., 2004).
We would like to acknowledge some limitations of this small pilot
study. Although there was a visually signiﬁcant difference between
FLT and FDG uptake by tumors at diagnosis in 4 of 6 patients, the overall
difference in SUV did not reach statistical signiﬁcance, likely due to the
small sample size. Also, although our results indicate the feasibility of
FLT and its potential usefulness in assessing chemoRT response in gyne-
cologic cancer, exact sensitivity and speciﬁcity of post-RT FLT-PET/CT
will need to be evaluated in future studies. Furthermore, larger samples
are needed to conﬁrm the validity of our ﬁndings and to determine the
diagnostic accuracy of FLT in this patient population,with the goal of de-
veloping quantitative imaging tools that will provide feasible method
for triaging treatment and a reliable measurement of the changes after
radiation therapy.5. Conclusion
Overall, FLT uptake in gynecologic cancers was lower than that of
FDG at initial diagnosis but was high enough to be detected visually
and to be quantiﬁable in all patients. FLT uptake markedly decreased
after chemoRT. These results likely indicate no signiﬁcant effect of in-
ﬂammation on FLT uptake. FLT may be a useful tool when assessing
the effects of chemoRT on gynecologic cancers and for optimizing
post-chemoRT brachytherapy planning.Disclosure
No potential conﬂict of interest relevant to this article is reported.
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